Nolvadex makes

Nolvadex makes

Get clear safety guidance for Nolvadex, including warnings, precautions, when to seek medical assistance, and how to use it correctly. Tamoxifen (Nolvadex® or Soltamox®) is a drug that treats hormone receptor-positive (hormone-positive) breast cancer. (Hormone-positive breast cancer is a type of cancer that needs estrogen and/or progesterone to grow.) Take this medication by mouth with or without food as directed by your doctor, usually once or twice daily for 5 years. Daily dosages greater than 20 milligrams are usually divided in half and taken twice a day, in the morning and evening, or as directed by your doctor. Nolvadex (Tamoxifen Citrate) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources. Tamoxifen (Nolvadex) is a hormone therapy. Hormone therapy is also called endocrine therapy. Tamoxifen has been used for over 40 years to treat hormone-receptor positive early, locally advanced and metastatic breast cancers. It’s used to treat breast cancer in both women and men. Tamoxifen, sold under the brand name Nolvadex among others, is a selective estrogen receptor modulator used to prevent breast cancer in women and men. [15] It is also being studied for other types of cancer. [15] Easy-to-read patient leaflet for Nolvadex. Includes indications, proper use, special instructions, precautions, and possible side effects. Learn about tamoxifen (Nolvadex) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives. Tamoxifen (Nolvadex®) is an oral anti-estrogen medication used in both the prevention and treatment of certain types of breast cancer. Overview: Tamoxifen is commonly used to treat certain types of breast cancer. It is also used to lower your risk of invasive breast cancer and keep some breast cancers from coming back. It blocks.

Leave a Reply

Your email address will not be published. Required fields are marked *

*
*